drugset / Trial / NCT05457829
Doxorubicin Hydrochloride Liposome Combined With Irinotecan (AI Regimen) Versus VIT Regimen in the Treatment of Relapsed and Refractory Pediatric Rhabdomyosarcoma: a Prospective, Open-label, Randomized Controlled, Multicenter, Phase II Clinical Study
RandomizedParallel-groupOpen-labelTreatment
Summary
This multicenter, randomized, controlled, open-label, prospective clinical trial was designed to evaluate the efficacy and safety of doxorubicin hydrochloride liposome injection in combination with irinotican (AI regimen) versus VIT regimen in the treatment of relapsed and refractory pediatric rhabdomyosarcoma.
Timeline
- Start
- 2023-12-30
- Primary completion
- 2026-06-30
- Completion
- 2026-07-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Doxorubicin | Other / unclassified | — | — |
| Comparator | Temozolomide | Small molecule | — | — |
| Comparator | Vincristine | Small molecule | — | — |
| Background | Irinotecan | Small molecule | — | — |